enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Growth Opportunities F. Forbion Buys 5,997 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the stock in a transaction dated Friday, October 4th. The shares were acquired at an average price of $6.54 per share, with a total value of $39,220.38. Following the completion of the purchase, the insider now directly owns 2,457,989 shares of the company’s stock, valued at approximately $16,075,248.06. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Stock Down 3.0 %

Shares of enGene stock opened at $9.02 on Friday. The stock has a market capitalization of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69. enGene Holdings Inc. has a twelve month low of $4.42 and a twelve month high of $43.00. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The business’s 50 day simple moving average is $6.71 and its 200-day simple moving average is $9.78.

enGene (NASDAQ:ENGN) last posted its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities research analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

ENGN has been the topic of several analyst reports. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of enGene in a report on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ENGN. Altitude Crest Partners Inc. bought a new stake in shares of enGene during the first quarter valued at approximately $2,039,000. Logos Global Management LP boosted its position in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after acquiring an additional 400,000 shares during the period. SR One Capital Management LP acquired a new position in shares of enGene during the second quarter valued at $4,715,000. Finally, Janus Henderson Group PLC bought a new stake in shares of enGene during the first quarter valued at about $17,095,000. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.